Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

NCT03867084 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

959

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC